Total Payments
$314,904
2024 Payments
$107,544
Companies
37
Transactions
289
Medicare Patients
679
Medicare Billing
$142,735
Payment Breakdown by Category
Consulting$242,658 (77.1%)
Travel$27,626 (8.8%)
Research$21,467 (6.8%)
Other$17,140 (5.4%)
Food & Beverage$6,013 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $242,658 | 89 | 77.1% |
| Travel and Lodging | $27,626 | 87 | 8.8% |
| Unspecified | $21,467 | 17 | 6.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,240 | 5 | 5.2% |
| Food and Beverage | $6,013 | 90 | 1.9% |
| Honoraria | $900.00 | 1 | 0.3% |
Payments by Type
General
$293,437
272 transactions
Research
$21,467
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $76,098 | 71 | $0 (2024) |
| ABBVIE INC. | $43,713 | 36 | $0 (2024) |
| Seagen Inc. | $19,998 | 14 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $18,670 | 11 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $15,815 | 18 | $0 (2024) |
| Amgen Inc. | $12,961 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $11,797 | 16 | $0 (2024) |
| Seattle Genetics, Inc. | $11,377 | 17 | $0 (2019) |
| F. Hoffmann-La Roche AG | $10,907 | 5 | $0 (2024) |
| ARRAY BIOPHARMA INC | $7,234 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107,544 | 91 | ABBVIE INC. ($26,883) |
| 2023 | $62,632 | 44 | AbbVie Inc. ($11,042) |
| 2022 | $34,474 | 30 | Bayer HealthCare Pharmaceuticals Inc. ($16,182) |
| 2021 | $21,738 | 10 | Bayer HealthCare Pharmaceuticals Inc. ($13,984) |
| 2020 | $25,485 | 22 | Bayer HealthCare Pharmaceuticals Inc. ($14,118) |
| 2019 | $8,972 | 13 | Seattle Genetics, Inc. ($4,479) |
| 2018 | $28,916 | 49 | Bayer HealthCare Pharmaceuticals Inc. ($10,085) |
| 2017 | $25,143 | 30 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,186) |
All Payment Transactions
289 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,580.00 | General |
| 11/25/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,540.00 | General |
| 11/22/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $5,480.00 | General |
| 11/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $423.46 | General |
| 11/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $64.00 | General |
| 11/22/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| 11/22/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $26.99 | General |
| 11/22/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $22.28 | General |
| 11/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $291.96 | General |
| 11/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $46.48 | General |
| 11/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $26.59 | General |
| 11/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nexavar (Drug), Stivarga | Consulting Fee | Cash or cash equivalent | $2,457.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $7,250.00 | General |
| 11/07/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $64.00 | General |
| 11/06/2024 | Astellas Pharma Global Development | Vyloy (Drug) | Consulting Fee | Cash or cash equivalent | $2,704.00 | General |
| Category: Oncology | ||||||
| 11/05/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 10/31/2024 | PFIZER INC. | BRAFTOVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $373.73 | General |
| 10/25/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $48.98 | General |
| 10/25/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $34.98 | General |
| 10/25/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $14.99 | General |
| 10/25/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $14.99 | General |
| 10/24/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $233.63 | General |
| 10/24/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $64.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
| COLORECTAL CANCER (CRC) VIRTUAL PANEL DISCUSSION | ABBVIE INC. | $5,075 | 2 |
| A Within-Trial Cost-Effectiveness Analysis of Panitumumab Compared With Bevacizumab in the First-Line Treatment of Patients With Wild-Type RAS Metastatic Colorectal Cancer in the US | Amgen Inc. | $2,143 | 1 |
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ABBVIE INC. | $2,065 | 2 |
| A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Conditions | ABBVIE INC. | $1,519 | 1 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ABBVIE INC. | $1,450 | 1 |
| A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | ABBVIE INC. | $1,013 | 1 |
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | AbbVie Inc. | $869.51 | 6 |
| A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors | Seattle Genetics, Inc. | $97.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 151 | 298 | $103,034 | $30,375 |
| 2022 | 3 | 145 | 371 | $129,400 | $35,118 |
| 2021 | 3 | 150 | 360 | $127,788 | $38,558 |
| 2020 | 6 | 233 | 487 | $159,266 | $38,684 |
Total Patients
679
Total Services
1,516
Medicare Billing
$142,735
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 73 | 184 | $63,296 | $18,313 | 28.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 57 | $14,250 | $5,246 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 35 | 35 | $17,150 | $4,385 | 25.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $5,346 | $1,516 | 28.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $2,992 | $914.36 | 30.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 82 | 275 | $94,600 | $25,583 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 45 | 45 | $22,050 | $6,049 | 27.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 51 | $12,750 | $3,486 | 27.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 89 | 282 | $97,008 | $29,599 | 30.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 47 | 47 | $23,030 | $6,310 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 31 | $7,750 | $2,649 | 34.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 97 | 253 | $87,032 | $20,624 | 23.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 110 | $28,050 | $6,121 | 21.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 46 | 46 | $22,540 | $5,485 | 24.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 50 | $12,500 | $3,503 | 28.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $7,776 | $2,207 | 28.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 12 | $1,368 | $744.57 | 54.4% |
About Dr. John Strickler, MD
Dr. John Strickler, MD is a Internal Medicine healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265523377.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Strickler, MD has received a total of $314,904 in payments from pharmaceutical and medical device companies, with $107,544 received in 2024. These payments were reported across 289 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($242,658).
As a Medicare-enrolled provider, Strickler has provided services to 679 Medicare beneficiaries, totaling 1,516 services with total Medicare billing of $142,735. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Durham, NC
- Active Since 09/27/2006
- Last Updated 09/30/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1265523377
Products in Payments
- Stivarga (Drug) $48,174
- TUKYSA (Drug) $15,964
- Vitrakvi (Drug) $13,870
- FRUZAQLA (Drug) $10,593
- Vectibix (Biological) $9,163
- Nexavar (Drug) $9,118
- BRAFTOVI (Drug) $9,074
- Avastin (Biological) $5,289
- Onivyde (Drug) $5,267
- Non-Covered Product (Drug) $4,232
- Abraxane (Drug) $4,160
- Non-Covered $3,796
- LUMAKRAS (Drug) $3,773
- Vyloy (Drug) $2,704
- TEVIMBRA (Drug) $2,625
- Enhertu (Drug) $2,205
- RYBREVANT (Drug) $2,025
- LONSURF (Drug) $1,980
- LIBTAYO (Biological) $1,673
- KEYTRUDA (Biological) $1,376
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Durham
Nirmish Shah, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Stephen Greene, M.d, M.D
Internal Medicine — Payments: $509,299
Internal Medicine $509,299
Dr. Robert Mentz, Md, MD
Internal Medicine — Payments: $466,052
Internal Medicine $466,052
Dr. Kevin Thomas, Md, MD
Internal Medicine — Payments: $294,767
Internal Medicine $294,767
Dr. Manesh Patel, M.d, M.D
Internal Medicine — Payments: $289,122
Internal Medicine $289,122
Dr. Camille Frazier-Mills, M.d, M.D
Internal Medicine — Payments: $187,940
Internal Medicine $187,940